Objective. To determine whether systemic juvenile idiopathic arthritis (JIA) susceptibility loci that were identified by candidate gene studies demonstrate association with systemic JIA in the largest study population assembled to date.
SNPs to anakinra treatment were evaluated in 38 US patients for whom treatment response data were available.
Results. We found no association between the previously reported 26 SNPs and systemic JIA. Expanded analysis of the regions containing the 26 SNPs revealed only 1 significant association: the promoter region of IL1RN (P < 1 3 10 -4
). Systemic JIA-associated SNPs correlated with IL1RN expression in LCLs, with an inverse correlation between systemic JIA risk and IL1RN expression. The presence of homozygous IL1RN high expression alleles correlated strongly with a lack of response to anakinra therapy (odds ratio 28.7 [95% confidence interval 3.2-255.8]).
Conclusion. In our study, IL1RN was the only candidate locus associated with systemic JIA. The implicated SNPs are among the strongest known determinants of IL1RN and interleukin-1 receptor antagonist levels, linking low expression with increased systemic JIA risk. Homozygous high expression alleles predicted nonresponsiveness to anakinra therapy, making them ideal candidate biomarkers to guide systemic JIA treatment. This study is an important first step toward the personalized treatment of systemic JIA.
Systemic juvenile idiopathic arthritis (JIA) is a rare, severe childhood inflammatory disease (1,2) that develops without an identifiable cause. It is marked by the presence of chronic arthritis that occurs along with profound systemic inflammation, including quotidian fever, lymphadenopathy, hepatosplenomegaly, a salmon pink evanescent skin rash, and serositis. It may also be accompanied by life-threatening complications, including pericardial effusion, interstitial lung disease, amyloidosis, and macrophage activation syndrome-a highly lethal secondary form of hemophagocytic lymphohistiocytosis.
Among children with systemic JIA,~50% develop a destructive form of chronic arthritis that persists throughout their lives.
Despite its unifying inflammatory characteristics, systemic JIA is a heterogeneous condition with 3 distinct disease courses and variable expression of clinical manifestations and complications (3) . Regardless of the disease course and specific manifestations, the goal of systemic JIA treatment is to extinguish the systemic inflammation as rapidly as possible, taking advantage of the early therapeutic "window of opportunity" in an effort to avoid the development of persistent arthritis (4) . Achievement of this goal is often complicated by the fact that children with systemic JIA do not respond uniformly to the currently available therapies (5, 6) . One subset of patients with systemic JIA responds to treatments targeting interleukin-1 (IL-1), another subset responds to IL-6-directed therapies, another responds to tumor necrosis factor (TNF) blockade, and some do not respond to any of these treatment strategies. Importantly, there is no objective determinant or biomarker that assists in predicting which therapeutic approach will be successful in individual patients, and thus there are often delays in amelioration of the systemic inflammation.
The pathophysiology of systemic JIA is poorly understood, as is the basis of its phenotypic heterogeneity. Due to its rare nature, most genetic studies of systemic JIA have utilized a candidate gene approach to examine small case-control collections. These studies have produced a list of more than 2 dozen single-nucleotide polymorphisms (SNPs) at 11 distinct susceptibility loci that were reported as systemic JIA-associated loci. These include the IL1A/B (7, 8) , GLI2 (7), IL1RN/PSD4 (7), IL1R2 (7), IL10/20 (9,10), IL6 (11, 12) , MVK (8), CCR5 (13), MIF (14), SLC26A2 (15), and TAPBP (16) loci (Table 1) . Importantly, the original evidence supporting these associations was modest and, in many cases, the associations were not observed in studies of independent populations. Despite these facts, these associations are regularly included in discussions of systemic JIA pathophysiology.
We have recently performed the largest genetic study of systemic JIA, a multinational effort that included children with systemic JIA from 9 countries (17,18). We identified 2 bona fide systemic JIA susceptibility loci and 24 additional loci suggestively associated with systemic JIA; however, there was no overlap between the peak systemic JIA susceptibility loci in our studies and those reported in the earlier candidate gene studies. To evaluate the relationship between systemic JIA risk and the systemic JIA susceptibility loci identified in candidate gene studies, we have undertaken a regional association study of the 11 reported candidate susceptibility loci in the International Childhood Arthritis Genetics Consortium (INCHARGE; for full membership of the INCHARGE and collaborating consortia, see Appendix A) systemic JIA case-control collection.
PATIENTS AND METHODS
Study design and participants. Directly observed and imputed SNP genotype data from the 9 case-control populations of the INCHARGE systemic JIA collection (17, 18) were evaluated for this study. The INCHARGE systemic JIA collection includes children who fulfill the International League of Associations for Rheumatology criteria for systemic JIA and controls from the US, the UK, Germany, Turkey, Italy, Brazil, Argentina, Canada, and Spain. SNP genotyping of genomic DNA from cases and controls was performed using HumanOmni1M arrays and an iScan reader (Illumina). SNP genotypes were stratified by country of origin and, where available, combined with existing SNP genotype data sets, in silico, from geographically matched healthy controls. Using standard metrics, each geographically defined stratum was subjected to rigorous quality control processes to remove samples and SNPs of poor quality. Ancestral outliers were removed from each of these strata using a combination of principal components analysis and multidimensional scaling. The degree of matching was assessed using genomic control inflation factors (k gc ), which were <1.004 for each of the 9 strata. Detailed information about patient and control populations included in the INCHARGE collection, along with technical descriptions and visualizations of the quality control processes and associated results, can be found in the supplementary material of our earlier reports (17, 18) .
For the present study, genotypes of SNPs residing in 11 candidate loci (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40498/abstract) were examined in 770 children with systemic JIA and 6,947 control samples from the US, the UK, Germany, Turkey, Italy, Brazil, Argentina, Canada, and Spain. For candidate loci defined by a single systemic JIA-associated SNP, the study interval was defined as AE100 kb from the position of that SNP. When >1 SNP association was present within a locus, the study interval was defined as AE100 kb from the mean of the positions of the reported systemic JIA-associated SNPs.
Statistical analysis. Association testing of candidate SNPs was performed under the additive model, adjusted for sex and ancestry-informative principal components, in each of the 9 systemic JIA case-control collections using SNPTEST version 2 (19) . Association results were then combined across collections using fixed-effect meta-analysis with GWAMA software (20) . Heterogeneity was evaluated using the I 2 statistic, and SNPs exhibiting moderate evidence of heterogeneity (I 2 > 0.5) were excluded from our analysis. Association data were visualized using SNP & Variation Suite 8 (SVS 8; Golden Helix) and custom R scripts (R version 3.4.0). Haplotype analysis and examination of linkage disequilibrium (LD) were performed using Haploview (21) . The SNP set was pruned for pairwise LD of r 2 < 0.5 by the estimation-maximization method with PLINK (22) to determine the number of independent SNPs in the study. The threshold for study-wide significance was defined using Bonferroni correction for the total number of independent SNPs across all candidate loci.
Gene expression analysis. The effect of systemic JIAassociated SNPs on gene and/or protein expression was examined using the HaploReg v4.1 database (23) . The correlation of systemic JIA-associated SNPs with gene expression was investigated by an integrated examination of RNA sequencing and wholegenome sequencing (WGS) data from subjects from the 1000 Genomes Project (24,25). RNA sequencing data from the set of 373 lymphoblastoid cell lines (LCLs) from the 1000 Genomes Project subjects were downloaded from the Geuvadis web site (http://www. geuvadis.org/web/geuvadis/RNAseq-project) and WGS data from the corresponding individuals were downloaded from the 1000 Genomes Project web site (http://www.internationalgenome.org/ data/). RNA sequencing data (normalized reads per kilobase per million) were stratified by systemic JIA risk allele genotype and the difference in relative expression between genotypes was evaluated using the nonparametric Kruskal-Wallis test. Box plots of relative expression were generated using R.
Therapeutic response analysis. The relationship between systemic JIA-associated IL1RN SNPs and therapeutic response to recombinant human IL-1 receptor antagonist (IL-1Ra) (anakinra) or tocilizumab treatment was examined in patients with systemic JIA from the US stratum, for whom therapeutic response data were available. This included 38 patients treated with anakinra and 14 patients treated with tocilizumab. Treatment response data were extracted from medical records by the treating pediatric rheumatologist, who encoded either "no response" or "any response" for each subject. "No response" was defined as no improvement of either fever (if present) or arthritis. "Any response" was defined as any degree of improvement in either fever or arthritis. We then tested for association between treatment response and systemic JIA-associated SNPs by logistic regression under the dominant model, using SVS 8. The threshold of significance for the association test was defined by Bonferroni correction for the number of independent SNPs tested, as defined by pairwise LD pruning (r 2 < 0.5).
RESULTS
Association testing of systemic JIA candidate SNPs and loci. We first performed association testing on the 26 SNPs for which associations with systemic JIA had been previously reported ( ]). By this standard, association meta-analyses of these 11 loci revealed a single significant association signal within the IL1RN locus (Figure 1 ). The association peak was located 4.3 kb upstream from IL1RN, with 3 SNPs exceeding the significance threshold and the top 7 SNPs in strong LD with one another (Figure 2 ). In fact, LD mapping and haplotype analysis of the top 25 SNPs within this locus revealed that the top 7 systemic JIA-associated SNPs were inherited as a part of a common haplotype (Figure 2) .
Systemic JIA-associated IL1RN variants and gene expression. A query of the HaploReg version 4.1 database revealed that many of the top systemic JIA-associated SNPs were known expression quantitative trait loci for IL1RN in whole blood (26) and LCLs (25) ( Table 2) . Moreover, a review of the literature showed that systemic JIA-associated SNPs also correlated with IL-1Ra protein levels in the largest study of genetic predictors of IL-1Ra levels (27) . The SNP that most strongly correlated with IL-1Ra in that study, rs4251961, was one of the top systemic JIA-associated SNPs and was a constituent of the 7 SNP haplotypes ( Figure 2 and Table 2 ). These observations were corroborated by our direct analyses of LCL RNA-sequencing data from 1000 Table 1 for other definitions).
† From fixed effect meta-analysis. ‡ Pairwise r 2 with rs55663133 using the estimation-maximization method in the US case-control population. § The top 7 systemic JIA-associated SNPs, which are inherited as a linkage disequilibrium block.
Genomes Project subjects (25) , which showed that the systemic JIA-associated SNPs were strongly correlated with IL1RN expression (Figure 3 ; also see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40498/abstract). Specifically, alleles that were protective against systemic JIA correlated with high IL1RN expression and those that were risk factors for systemic JIA correlated with decreased IL1RN expression (Figure 3) . Importantly, all 3 of the studies mentioned above parsimoniously demonstrated that systemic JIA risk alleles of the top 42 systemic JIA-associated SNPs were correlated with decreased levels of IL1RN expression or circulating IL-1Ra protein (Figure 3) .
Systemic JIA-associated IL1RN variants and response to anakinra therapy in systemic JIA. Given that the response of systemic JIA to treatment with recombinant human IL-1Ra (anakinra) is variable, we hypothesized Figure 3 . Relationship of IL1RN expression and interleukin-1 receptor antagonist (IL-1Ra) protein levels with systemic JIA-associated SNPs. A and B, IL1RN expression determined by RNA sequencing (Lappalainen et al [25] ) is shown, stratified by genotype, for representative systemic JIA-associated SNPs. Data are shown as box plots. Each symbol represents a single patient. Boxes represent the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. C-E, Dot plots depicting all SNPs with reported correlations with IL1RN expression (C and D) or IL-1Ra protein levels (E) (Westra et al [26] , Lappalainen et al [25] , and Herder et al [27] , respectively). SNPs among the top 42 systemic JIA-associated SNPs are shown in green (systemic JIA protective alleles) and gold (systemic JIA risk alleles), and the top 7 systemic JIA-associated SNPs are shown in red. Horizontal lines represent the median. RPKM = reads per kilobase per million; LCLs = lymphoblastoid cell lines (see Figure 1 for other definitions).
that individuals with the highest genetically encoded levels of IL-1Ra may be more likely to experience nonresponse to anakinra treatment than those with lower genetically encoded IL-1Ra levels. To evaluate this possibility, we examined clinical and SNP genotype data in 38 patients with systemic JIA from the US collection who had received anakinra and for whom clinical data were available. Within this group of anakinra-treated patients, there were 9 nonresponders and 29 "any responders." An examination of the top 7 systemic JIA-associated IL1RN SNPs revealed that for each SNP, homozygosity for the IL1RN high expression alleles was associated with nonresponse to anakinra treatment (P < 0.05) ( Table 3) . SNP rs555447483 showed the strongest association with nonresponsiveness to anakinra (P = 7.7 9 10 -4
; odds ratio 28.7 [95% confidence interval 3.2-255.8]), with homozygous high expression alleles predicting nonresponse with a sensitivity of 92% and a specificity of 71%.
In order to determine whether the relationship between these SNPs and nonresponsiveness to systemic JIA treatment was specific to anakinra, we performed an identical examination of the 14 patients with systemic JIA from the US case-control collection who were treated with tocilizumab (an anti-IL-6 monoclonal antibody). Within this group, which included 3 tocilizumab nonresponders and 11 tocilizumab "any responders," we found no association between systemic JIA-associated IL1RN SNPs and treatment response (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40498/abstract). Moreover, 8 of the 14 patients who were treated with tocilizumab were anakinra nonresponders who had received tocilizumab as second-line treatment. Among the 8 anakinra nonresponders, 6 were tocilizumab "any responders." Taken together, these findings support the hypothesis that systemic JIA-associated IL1RN SNPs specifically predict nonresponsiveness of systemic JIA to anakinra treatment, as opposed to identifying individuals whose systemic JIA is more broadly refractory to treatment.
DISCUSSION
Through examination of common genetic variants at 11 previously reported systemic JIA susceptibility loci in the INCHARGE systemic JIA collection, this study has revealed 3 important findings. First, it has demonstrated that the IL1RN locus is a bona fide systemic JIA susceptibility locus. Second, the study has shown that genetically encoded high expression of IL1RN and production of IL1Ra are protective against systemic JIA (and conversely that genetically encoded low expression and production are risk factors for developing the illness). Most importantly, it has shown that homozygosity for the high expression alleles of systemic JIA-associated IL1RN SNPs is strongly associated with nonresponsiveness to anakinra treatment in patients with systemic JIA. The original studies that described these 11 candidate loci revealed modest associations that were identified in small case-control collections (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . At most of these loci, the associations with systemic JIA were not observed in subsequent studies of other populations, which calls into question their proposed relationships with systemic JIA. We sought to evaluate these associations more rigorously by using the INCHARGE systemic JIA collection, which provided greater statistical power than was present in any previous study of these loci while also allowing for internal validation through the examination of 9 independent populations.
Using this approach, we found that only 1 of these candidate loci, IL1RN, was associated with systemic JIA. At this locus, we observed 3 systemic JIA-associated SNPs that tagged a 7-SNP haplotype in the promoter region of IL1RN, as well as a cluster of 39 other SNPs with intermediate evidence of association with systemic Table 1 for other definitions).
JIA. Importantly, the IL1RN association signal identified in the present study did not include any of the SNPs that were previously reported as being associated with systemic JIA (Table 1) , or any SNPs that were in strong LD with those previously reported SNPs (Figure 1 ; also see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40498/abstract). This observation suggests that previous candidate gene studies of systemic JIA could have been negatively impacted by poor statistical power, as has been the case in studies of other genetically complex diseases, such as schizophrenia (28) . Given that the association signal of the IL1RN locus was within the promoter region, we hypothesized that these SNPs may influence systemic JIA risk by altering gene expression. By examining previously published gene expression studies and integrating our association data with publicly available gene expression data sets, we found that the risk alleles of the top 42 systemic JIA-associated IL1RN SNPs correlated with reduced IL1RN expression and circulating IL-1Ra levels ( Figure 2 and Table 2 ). Furthermore, we observed that the top 7 systemic JIAassociated SNPs were among the SNPs most strongly associated with IL1RN expression levels in whole blood and LCLs, and with circulating levels of IL-1Ra protein, in previous studies (25) (26) (27) (Table 2) . Taken together these observations suggest that the systemic JIA-associated IL1RN SNPs influence systemic JIA risk through their effect on IL1RN expression and production of IL-1Ra.
IL-1Ra is a well-documented, positive, acute-phase protein (29) and it has been shown to be highly expressed in the blood of children with active systemic JIA (30, 31) . Therefore, one would expect that gene expression studies would demonstrate increased expression of IL1RN in children with active systemic JIA as compared to healthy subjects or children with quiescent systemic JIA. There have been several studies that have examined gene expression in systemic JIA peripheral blood mononuclear cells. In 1 of these studies, the expression of positive acute-phase genes was up-regulated in children with systemic JIA and the authors noted that IL1RN was among this cluster (32) . However, 3 other studies showed no relationship between systemic JIA and IL1RN expression (33) (34) (35) .
There are a few potential reasons for these conflicting results. It is possible that these studies lacked the statistical power to identify a relationship between systemic JIA and IL1RN expression, given that they were undertaken in relatively small numbers of systemic JIA cases. It is also possible that these studies were affected by confounding variables that altered IL1RN expression in the systemic JIA patients, such as the duration of systemic JIA, the level of disease activity, or the treatment administered. In the present study, by examining the correlation between systemic JIA-associated IL1RN variants and gene expression in healthy individuals, we were able to identify the relationship between IL1RN expression and systemic JIA without the interference of these potential confounders.
In addition to evaluating disease risk, we demonstrated that high expression alleles of systemic JIAassociated IL1RN SNPs were strongly associated with nonresponsiveness to anakinra therapy. The lack of association between these SNPs and nonresponsiveness to tocilizumab treatment suggests that these SNPs are specifically associated with anakinra nonresponsiveness, as opposed to being associated with more global treatment resistance. In the context of the biphasic hypothesis of systemic JIA pathophysiology, new-onset systemic JIA is treated with the goal of rapidly inducing remission within the therapeutic window of opportunity (4) .
Anakinra is commonly chosen as the first line treatment because its effects can be observed within days of treatment initiation and because dosing can be rapidly escalated, but it is not effective in all patients (36) . In the subset of systemic JIA patients who ultimately do not respond to anakinra, the time to remission is prolonged due to the unsuccessful course of anakinra treatment. The findings of this study can be used to identify the subset of children with systemic JIA who are unlikely to respond to anakinra and to facilitate the selection of an alternative treatment. In doing so, the delay associated with a firstline therapeutic failure can be avoided, time to remission can be reduced, and unnecessary exposure to the risks of anakinra treatment can be prevented. IL1RN SNP genotypes are the first candidate biomarkers that can prospectively guide therapeutic decision-making in systemic JIA.
Despite the strength of the findings, it is important to consider the potential limitations of our study. The study evaluated genetic associations in 9 independent systemic JIA case-control collections. For future studies, it will be important to examine the IL1RN region in larger, independent groups of patients. There were also several limitations to the evaluation of genetic predictors of anakinra response. Therapeutic response to anakinra was examined in 38 systemic JIA patients, which is a relatively small group. The therapy regimen in anakinra-treated patients was not standardized, with potential variation in the drug dosing and duration, timing of dose escalation, and concurrent treatment with other agents (i.e., glucocorticoids). Additionally, the clinical response data were extracted from medical records in a post hoc analysis and clinical response metrics were not standardized. We anticipated that these factors would complicate differentiating incomplete and complete response, but should not influence the identification of nonresponsiveness. Therefore, we chose to compare nonresponse to "any response." Nonetheless, it will be important to evaluate the correlation between IL1RN SNPs and response to anakinra in prospective studies of larger numbers of patients treated and monitored in a standardized manner.
By identifying a prospective biomarker capable of guiding the treatment of systemic JIA, this study brings precision medicine to rheumatology clinical practice. In future investigations, it will be important to determine whether these findings are generalizable beyond anakinra and systemic JIA. For example, can the IL1RN SNPs predict response to other IL-1-directed therapies, such as monoclonal anti-IL-1b antibodies (canakinumab) or the IL-1 trap (rilonacept), in systemic JIA? Similarly, these SNPs may predict therapeutic response to anakinra (or other IL-1-directed therapies) in conditions other than systemic JIA, such as adult-onset Still's disease or monogenic autoinflammatory diseases. Given that recently published reports have described studies in which canakinumab treatment significantly reduced the risk of recurrent cardiovascular events (37) , as well as the incidence of and mortality from lung cancer (38) , it is even possible that the utility of this prospective biomarker may extend beyond the field of rheumatology.
